# Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

> **NCT03989349** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 787 (actual)

## Conditions studied

- Moderate-to-Severe Atopic Dermatitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Nemolizumab

## Key facts

- **NCT ID:** NCT03989349
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-30
- **Primary completion:** 2022-02-23
- **Final completion:** 2022-09-26
- **Target enrollment:** 787 (ACTUAL)
- **Last updated:** 2024-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03989349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03989349, "Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03989349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*